Drugs

Ten Years of Experience with Biphasic Insulin Aspart 30
From Drug Development to the Latest Clinical Findings

Liebl A, et al.

Supplemental Digital Content

This Supplemental Digital Content contains the information referred to in the full version of this article, which can be found at http://adisonline.com/drugs.

Adis © 2012 Liebl A, et al., publisher and licensee Springer International Publishing AG. This is an open access article published under the terms of the Creative Commons License “Attribution-NonCommercial-NoDerivative 3.0” (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution, and reproduction, provided the original work is properly cited and not altered.
Figure S1

The substitution of a proline (dark structure) with an aspartic acid residue at B28 (gray structure) inhibits the van der Waals interaction between the B28 proline and B23 glycine. Reproduced from Brange et al.,[13] with permission from Macmillan Publishers Ltd. © 1988.

Figure S2

Rates of low interstitial glucose. Reproduced from McNally et al.,[20] with permission from the American Diabetes Association. © 2007 American Diabetes Association. BHI, biphasic human insulin; BIASp, biphasic insulin aspart; IG, interstitial glucose
Pharmacodynamic profile of BIAsp 30 compared with basal–bolus insulin glargine and glulisine. Reproduced from Heise et al.,[23] with permission from the American Diabetes Association. © 2009 American Diabetes Association. BIAsp, biphasic insulin aspart; OD, once daily; TID, three-times daily.
### Table S1. Titration algorithm for BIAsp 30\textsuperscript{[23]}

<table>
<thead>
<tr>
<th>Pre-meal blood glucose level (mmol/L)</th>
<th>BIAsp 30 adjustment (U)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;4.4</td>
<td>–2</td>
</tr>
<tr>
<td>4.4–6.1</td>
<td>0</td>
</tr>
<tr>
<td>6.2–7.8</td>
<td>+2</td>
</tr>
<tr>
<td>7.9–10</td>
<td>+4</td>
</tr>
<tr>
<td>&gt;10</td>
<td>+6</td>
</tr>
</tbody>
</table>

BIAsp, biphasic insulin aspart

### Table S2. Cost-effectiveness terminology

<table>
<thead>
<tr>
<th>Cost-effectiveness terminology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cost-effective</strong></td>
</tr>
<tr>
<td>The increased cost of the intervention is viewed as worthwhile due to clinical benefits of the intervention</td>
</tr>
<tr>
<td><strong>Dominant</strong></td>
</tr>
<tr>
<td>Total costs in the intervention are lower and the intervention is more effective than the comparator</td>
</tr>
</tbody>
</table>

**ICER:** Incremental cost-effectiveness ratio
The additional cost to gain a particular clinical benefit (e.g., an ICER of US$10,000 per QALY gained)

**QALE:** Quality-adjusted life expectancy
Measures of the length and quality of life, either as total life expectancy or additional years gained. Quality of life is measured on a scale where 1.0 = perfect health and 0.0 = dead
Reference list


http://www.medicines.org.uk/EMC/medicine/8591/SPC/NovoMix+30+Penfill+100+U+ml%2c+NovoMix+30+FlexPen+100+U+ml/ [Last accessed 12 September 2011].


http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021172s045s049lbl.pdf [Last accessed 17 November 2011].


54. Christiansen JS, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with


97. Gao Y, Guo XH. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin < 7%: the results from the China cohort of the PRESENT study. Chin Med J (Engl) 2010; 123: 1107-111.


